Latest Breaking News On - ஆரோக்கியம் தொடர்புடையது - Page 6 : comparemela.com

Home / Top News / Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics (“Aardvark”) to acquire Aardvark’s proprietary formulation, Delayed Burst Release Low Dose Naltrexone (DBR-LDN), or ARD-301, for the treatment of chronic pain, fibromyalgia, and chroni

New yorkUnited statesJaisim shahAlexis nahamaTien leeNeda fareghMary ann fitzcharlesBrian johnsonStephen faraoneScilex holdings companyDrug administrationDepartment of psychiatryNational fibromyalgia associationJournal of the american medical associationHealth relatedScilex holding company